Cancer Genetics reports 93% accuracy for kidney cancer test

|About: Cancer Genetics, Inc. (CGIX)|By:, SA News Editor

Nano cap Cancer Genetics' (CGIX) microarray kidney cancer test delivers impressive results in a collaborative study of 188 samples with the Cleveland Clinic. The test demonstrated a sensitivity of 93% and specificity of 99%.

The company currently offers the test as a service (lab developed test or LDT).

The test is performed on kidney, either paraffin-embedded or fine needle aspirate requiring only 2 micrograms of tissue.

60,000 new cases of kidney cancer occur in the US each year with 14,000 deaths. 200,000 - 240,000 cases require annual assessment.